Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162449 | PMC |
| http://dx.doi.org/10.1089/pop.2014.0060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced brain tumor detection and segmentation using densely connected convolutional networks with stacking ensemble learning.
Comput Biol Med
January 2025
Emerging Technologies Research Lab (ETRL), College of Computer Science and Information Systems, Najran University, Najran, 61441, Saudi Arabia; Department of Computer Science, College of Computer Science and Information Systems, Najran University, Najran, 61441, Saudi Arabia. Electronic address:
- Brain tumors (BT), both benign and malignant, pose a substantial impact on human health and need precise and early detection for successful treatment. Analysing magnetic resonance imaging (MRI) image is a common method for BT diagnosis and segmentation, yet misdiagnoses yield effective medical responses, impacting patient survival rates. Recent technological advancements have popularized deep learning-based medical image analysis, leveraging transfer learning to reuse pre-trained models for various applications.
View Article and Find Full Text PDFSEPO-FI: Deep-learning based software to calculate fusion index of muscle cells.
Comput Biol Med
January 2025
School of Computer Science, Chungbuk National University, Cheongju 28644, Republic of Korea. Electronic address:
The fusion index is a critical metric for quantitatively assessing the transformation of in vitro muscle cells into myotubes in the biological and medical fields. Traditional methods for calculating this index manually involve the labor-intensive counting of numerous muscle cell nuclei in images, which necessitates determining whether each nucleus is located inside or outside the myotubes, leading to significant inter-observer variation. To address these challenges, this study proposes a three-stage process that integrates the strengths of pattern recognition and deep-learning to automatically calculate the fusion index.
View Article and Find Full Text PDFLeveraging molecular dynamics, physicochemical, and structural analysis to explore OMP33-36 protein as a drug target in Acinetobacter baumannii: An approach against nosocomial infection.
J Mol Graph Model
January 2025
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomtinagar Extension, Lucknow, 226028, India; Research Cell, Amity University Uttar Pradesh, Lucknow Campus, India. Electronic address:
The Acinetobacter baumannii is a member of the "ESKAPE" bacteria responsible for many serious multidrug-resistant (MDR) illnesses. This bacteria swiftly adapts to environmental cues leading to the emergence of multidrug-resistant variants, particularly in hospital/medical settings. In this work, we have demonstrated the outer membrane protein 33-36 (Omp33-36) porin as a potential therapeutic target in A.
View Article and Find Full Text PDFGrowth hormone improves the pregnancy outcomes in poor ovarian responders undergoing in vitro fertilization: an umbrella review.
J Assist Reprod Genet
January 2025
Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
Poor ovarian response (POR) significantly impacts the success of assisted reproductive technology (ART), and growth hormone (GH) has been proposed as an adjuvant treatment to improve outcomes in POR patients undergoing in vitro fertilization (IVF). A systematic review and meta-analysis were conducted to evaluate the effectiveness of GH in enhancing pregnancy outcomes, registering a protocol on PROSPERO and searching multiple databases up to September 2023. Twelve systematic reviews/meta-analysis and 20 randomized controlled trials (RCTs) involving 1984 patients were included.
View Article and Find Full Text PDFFrom Vision to Reality: The EU's Pharmaceutical Reforms and the Path to Improved Access.
Pharmacoecon Open
January 2025
Department of Health Policy and Medical Technology Research Group, LSE Health, London School of Economics and Political Science, London, UK.
Disparities in access to oncology medicines in European Union (EU) member states can impact patient outcomes profoundly, with availability and timely access varying significantly across and within member states. This paper discusses the intersection of the new European Health Technology Assessment Regulation (HTAR), the provisions of the proposed pharmaceutical legislation and their potential impacts on access to oncology medicines across EU member states. The HTAR, seeking to standardise the clinical evaluation of new medicines, has the potential to streamline the evaluation process but also risks oversimplifying diverse national healthcare needs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!